Biodefense Market, By Product (Anthrax, Small Pox, Botulism, Radiation, and Others), By End User (Hospitals, Ambulatory Care Centers, Research Organizations, Military, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle

Biodefense Market, By Product (Anthrax, Small Pox, Botulism, Radiation, and Others), By End User (Hospitals, Ambulatory Care Centers, Research Organizations, Military, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biodefense is a military or emergency response term that is frequently discussed in the context of bio-war or bioterrorism. Biodefense also refers to actions taken to restore biosecurity to a group of organisms that are or may be vulnerable to biological threats or infectious diseases. A biological attack, also known as bioterrorism, is the deliberate release of viruses, bacteria, or other germs capable of sickening or killing people, livestock, or crops. The bacteria that causes anthrax, Bacillus anthracis, is considered as one of the most likely agents to be used in a biological attack.

Market Dynamics

Market players and some global foundations are focused on developing vaccines against Nipah Virus, this could contribute to the growth of the global biodefense market over the forecast period. For instance on March 13, 2021, the Coalition for Epidemic Preparedness Innovations (CEPI), a global foundation that takes donations from philanthropic organizations, funded the first Nipah virus vaccine candidate to enter Phase 1 clinical trials. The Phase 1 trial is a randomized, placebo-controlled dose-finding study to assess the safety, tolerability, and immunogenicity of the HeV-sG-V Nipah vaccine candidate. The study is being conducted at Cincinnati Children's Hospital Medical Center in Cincinnati, U.S., and is sponsored by Auro Vaccines LLC, a wholly owned indirect subsidiary of Aurobindo Pharma Ltd., and led by Program for Appropriate Technology in Health (PATH), a global non-profit organization.

Market players are focusing on product launches, which is expected to strengthen their position in the global biodefense market. For instance, on July 01, 2021, Johnson & Johnson, world’s largest healthcare company announced that the European Commission (EC) approved its subsidiary Janssen Pharmaceutical Companies' Ebola vaccine regimen for the prevention of Ebola Virus Disease.

Market players are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, this is expected to drive the growth of the global biodefense market. For instance, on February 26, 2021, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, partnered with Southern Research, a non-profit scientific research organization, to develop a potential COVID-19 vaccine based on Tonix's proprietary horsepox vaccine platform (TNX-1800).

Key features of the study:
This report provides an in-depth analysis of global biodefense market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global biodefense market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Emergent Biosolutions Inc., SIGA Technologies Inc., Bavarian Nordic A/S, Elusys Therapeutics Inc., Ichor Medical Systems Inc., Amgen Inc., Cleveland BioLabs Inc., Dynavax Technologies Corporation, Alnylam Pharmaceuticals Inc., and XOMA Corporation.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global biodefense market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global biodefense market.
Detailed Segmentation:
Global Biodefense Market, By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
Global Biodefense Market, By End User:
Hospitals
Ambulatory Care Centers
Research Organizations
Military
Others
Global Biodefense Market, By Region:
North America
By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
By End User:
Hospitals
Ambulatory Care Centers
Military
Others
By Country:
U.S.
Canada
Latin America
By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
By End User:
Hospitals
Ambulatory Care Centers
Military
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
By End User:
Hospitals
Ambulatory Care Centers
Military
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
By End User:
Hospitals
Ambulatory Care Centers
Military
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East
By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
By End User:
Hospitals
Ambulatory Care Centers
Military
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product:
Anthrax
Small Pox
Botulism
Radiation
Others
By End User:
Hospitals
Ambulatory Care Centers
Military
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Emergent Biosolutions Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
SIGA Technologies Inc.
Bavarian Nordic A/S
Elusys Therapeutics Inc.
Ichor Medical Systems Inc.
Amgen Inc.
Cleveland BioLabs Inc.
Dynavax Technologies Corporation
Alnylam Pharmaceuticals Inc.
XOMA Corporation.

“*” marked represents similar segmentation in other categories in the respective section.